|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...9596979899100101102103104105...156157» |
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion date: An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) (clinicaltrials.gov) - May 18, 2014
P=N/A, N=51, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jun 2014 --> Aug 2014
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion date: A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 18, 2014
P=N/A, N=50, Completed, Sponsor: Hoffmann-La Roche
Trial completion date: Jun 2014 --> Aug 2014 Trial completion date: Apr 2014 --> Mar 2014
- Biomarker, Enrollment open: Salivary Biomarkers for Sj (clinicaltrials.gov) - May 18, 2014
P=N/A, N=420, Recruiting, Sponsor: University of California, Los Angeles
Trial completion date: Apr 2014 --> Mar 2014 Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche
Enrollment closed, Monotherapy: GATEWAY II: Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate (clinicaltrials.gov) - May 18, 2014
P2, N=90, Active, not recruiting, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Trial completion: Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study (clinicaltrials.gov) - May 18, 2014
P4, N=100, Completed, Sponsor: University of Colorado Denver School of Medicine Barbara Davis Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion: A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 18, 2014
P=N/A, N=50, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open: An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 18, 2014
P=N/A, N=1186, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- |||| Trimesta (estriol oral) / Synthetic Biologics
Trial completion: A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - May 14, 2014
P2, N=158, Completed, Sponsor: University of California, Los Angeles
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- || AMG 811 / Amgen
Trial primary completion date: Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis (clinicaltrials.gov) - May 14, 2014
P1, N=56, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Trial primary completion date: Apr 2014 --> Jun 2014
- rofecoxib (TRM-201) / Tremeau Pharma
Trial termination: 12-Week No-Rofecoxib Plus Aspirin Endoscopy Study (0782-003) (clinicaltrials.gov) - May 14, 2014
P2, N=49, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Apr 2014 --> Jun 2014 Completed --> Terminated
- Norditropin (somatropin) / Novo Nordisk, Insuman Rapid (recombinant human insulin) / Sanofi
Trial initiation date: Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. (clinicaltrials.gov) - May 14, 2014
P=N/A, N=10, Recruiting, Sponsor: University of Aarhus
Completed --> Terminated Initiation date: Apr 2014 --> May 2014
- | AMG 811 / Amgen
Trial completion date: Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis (clinicaltrials.gov) - May 14, 2014
P1, N=56, Active, not recruiting, Sponsor: Amgen
Initiation date: Apr 2014 --> May 2014 Trial completion date: Jul 2014 --> Aug 2014
- Clinical: RAHExercise: Hand Exercises for Women With Rheumatoid Arthritis and Impaired ADL Ability: an Exploratory Trial (clinicaltrials.gov) - May 14, 2014
P=N/A, N=90, Recruiting, Sponsor: Parker Research Institute
- fingolimod / Generic mfg.
Clinical: Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya (clinicaltrials.gov) - May 14, 2014
P=N/A, N=20, Recruiting, Sponsor: Stony Brook University
- Norditropin (somatropin) / Novo Nordisk, Insuman Rapid (recombinant human insulin) / Sanofi
Enrollment open: Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. (clinicaltrials.gov) - May 14, 2014
P=N/A, N=10, Recruiting, Sponsor: University of Aarhus
Trial completion date: Jul 2014 --> Aug 2014 Not yet recruiting --> Recruiting
- Trial completion, IO biomarker: Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health (clinicaltrials.gov) - May 14, 2014
P1, N=57, Completed, Sponsor: Johns Hopkins University
Not yet recruiting --> Recruiting Recruiting --> Completed
- || Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Trial completion date: A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy (clinicaltrials.gov) - May 14, 2014
P2, N=274, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Trial completion date: Jun 2014 --> May 2014
- ||||| Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
New P2 trial: A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM) (clinicaltrials.gov) - May 14, 2014
P2, N=330, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- |||| Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Trial completion: A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy (clinicaltrials.gov) - May 14, 2014
P2, N=274, Completed, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jun 2014 --> May 2014 Active, not recruiting --> Completed
- New P1/2 trial: Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation (clinicaltrials.gov) - May 13, 2014
P1/2, N=8, Recruiting, Sponsor: Seoul National University Hospital
- ||| Clinical: CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients (clinicaltrials.gov) - May 13, 2014
P=N/A, N=60, Not yet recruiting, Sponsor: University of Florida
- ||| Clinical: TC-A Registration Study (clinicaltrials.gov) - May 13, 2014
P=N/A, N=156, Not yet recruiting, Sponsor: Smith & Nephew Medical (Shanghai) Ltd
- prednisone / Generic mfg.
Trial initiation date: A Study of the Effects of Oral Prednisone in Patients With Rheumatoid Arthritis (MK0000-088) (clinicaltrials.gov) - May 13, 2014
P1, N=45, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Initiation date: Oct 2008 --> Sep 2008
- ||| Enbrel (etanercept) / Pfizer, Amgen
Enrollment closed: Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening (clinicaltrials.gov) - May 13, 2014
P4, N=320, Active, not recruiting, Sponsor: Pfizer
Initiation date: Oct 2008 --> Sep 2008 Recruiting --> Active, not recruiting
- New P3 trial: An Investigation of rhTPO With Different Frequencies in the Management of ITP (clinicaltrials.gov) - May 13, 2014
P3, N=30, Recruiting, Sponsor: Shandong University
- || spebrutinib (CC-292) / BMS
Trial primary completion date: Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis (clinicaltrials.gov) - May 12, 2014
P2, N=80, Recruiting, Sponsor: Celgene Corporation
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2014 --> Sep 2014
- | methylprednisolone sodium succinate / Generic mfg.
Clinical: A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. (clinicaltrials.gov) - May 12, 2014
P3, N=36, Recruiting, Sponsor: The Hospital for Sick Children
Trial primary completion date: Aug 2014 --> Sep 2014 Trial primary completion date: Jan 2009 --> Dec 2014
- || spebrutinib (CC-292) / BMS
Trial completion date: Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis (clinicaltrials.gov) - May 12, 2014
P2, N=80, Recruiting, Sponsor: Celgene Corporation
Trial primary completion date: Jan 2009 --> Dec 2014 Trial completion date: Oct 2014 --> Nov 2014
- methylprednisolone sodium succinate / Generic mfg.
Clinical: A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. (clinicaltrials.gov) - May 12, 2014
P3, N=36, Recruiting, Sponsor: The Hospital for Sick Children
Trial completion date: Oct 2014 --> Nov 2014 Trial completion date: Jan 2010 --> Jul 2015
- Trial primary completion date: Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients (clinicaltrials.gov) - May 12, 2014
P=N/A, N=135, Recruiting, Sponsor: Keesler Air Force Base Medical Center
Trial completion date: Jan 2010 --> Jul 2015 Trial primary completion date: Jan 2014 --> Jan 2015
- Trial completion date: Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients (clinicaltrials.gov) - May 12, 2014
P=N/A, N=135, Recruiting, Sponsor: Keesler Air Force Base Medical Center
Trial primary completion date: Jan 2014 --> Jan 2015 Trial completion date: Jan 2014 --> Jan 2015
- || staphylococcal protein A (PRTX-100) / Protalex
Trial primary completion date, Combination therapy: SPARTA: Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis (clinicaltrials.gov) - May 12, 2014
P1, N=64, Active, not recruiting, Sponsor: Protalex, Inc.
Trial completion date: Jan 2014 --> Jan 2015 Trial primary completion date: Apr 2014 --> Aug 2014
- Orencia (abatacept) / BMS
Trial primary completion date: Islet Transplantation Using Abatacept (clinicaltrials.gov) - May 12, 2014
P2, N=5, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Apr 2014 --> Aug 2014 Trial primary completion date: Dec 2011 --> Oct 2015
- Trial primary completion date: Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression (clinicaltrials.gov) - May 12, 2014
P2, N=8, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Dec 2011 --> Oct 2015 Trial primary completion date: Dec 2011 --> Oct 2015
- | staphylococcal protein A (PRTX-100) / Protalex
Trial completion date, Combination therapy: SPARTA: Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis (clinicaltrials.gov) - May 12, 2014
P1, N=64, Active, not recruiting, Sponsor: Protalex, Inc.
Trial primary completion date: Dec 2011 --> Oct 2015 Trial completion date: Aug 2014 --> Sep 2014
- Orencia (abatacept) / BMS
Trial completion date: Islet Transplantation Using Abatacept (clinicaltrials.gov) - May 12, 2014
P2, N=5, Active, not recruiting, Sponsor: Emory University
Trial completion date: Aug 2014 --> Sep 2014 Trial completion date: Dec 2014 --> Oct 2016
- Trial completion date: Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression (clinicaltrials.gov) - May 12, 2014
P2, N=8, Active, not recruiting, Sponsor: Emory University
Trial completion date: Dec 2014 --> Oct 2016 Trial completion date: Dec 2014 --> Oct 2016
- Trial primary completion date: Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo (clinicaltrials.gov) - May 12, 2014
P=N/A, N=1500, Active, not recruiting, Sponsor: St. Luke's-Roosevelt Hospital Center
Trial completion date: Dec 2014 --> Oct 2016 Trial primary completion date: Mar 2012 --> Mar 2015
- Trial completion date: Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo (clinicaltrials.gov) - May 12, 2014
P=N/A, N=1500, Active, not recruiting, Sponsor: St. Luke's-Roosevelt Hospital Center
Trial primary completion date: Mar 2012 --> Mar 2015 Trial completion date: Mar 2012 --> Mar 2015
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P3 trial: A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia ?ITP? (clinicaltrials.gov) - May 12, 2014
P3, N=60, Recruiting, Sponsor: Shandong University
- | Victoza (liraglutide) / Novo Nordisk
Enrollment open: ADJUNCT TWO: The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes (clinicaltrials.gov) - May 12, 2014
P3, N=804, Recruiting, Sponsor: Novo Nordisk A/S
Trial completion date: Mar 2012 --> Mar 2015 Not yet recruiting --> Recruiting
- Enrollment closed: Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo (clinicaltrials.gov) - May 12, 2014
P=N/A, N=1500, Active, not recruiting, Sponsor: St. Luke's-Roosevelt Hospital Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Enrollment closed: Dose-finding Study of MT-1303 (clinicaltrials.gov) - May 11, 2014
P2, N=400, Active, not recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Clinical: Mindfulness-based Stress Reduction in Multiple Sclerosis (clinicaltrials.gov) - May 11, 2014
P=N/A, N=50, Not yet recruiting, Sponsor: NHS Greater Glasgow and Clyde
- ||| Tysabri (natalizumab) / Biogen
Clinical: Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri (clinicaltrials.gov) - May 11, 2014
P=N/A, N=400, Enrolling by invitation, Sponsor: Biogen Idec
- ||||| fingolimod / Generic mfg.
New P4 trial: Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya (clinicaltrials.gov) - May 11, 2014
P4, N=400, Recruiting, Sponsor: McGill University
- |||||||||| Cyltezo (adalimumab biosimilar) / Boehringer Ingelheim
New P3 trial: VOLTAIRE-RA: BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - May 11, 2014
P3, N=600, Not yet recruiting, Sponsor: Boehringer Ingelheim
- ||||||| hydroxychloroquine / Generic mfg.
Trial completion: Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion (clinicaltrials.gov) - May 11, 2014
P3, N=103, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - May 11, 2014
P3, N=15, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Trial primary completion date: Sep 2014 --> Nov 2014
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial withdrawal: A Non-Interventional Study in Patients With Rheumatoid Arthritis Who Are Treated With RoActemra/Actemra (Tocilizumab) (clinicaltrials.gov) - May 11, 2014
P=N/A, N=0, Withdrawn, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2014 --> Nov 2014 Not yet recruiting --> Withdrawn